Emmaus Medical, Inc. is a biopharmaceutical company focused on sickle cell disease, a genetic disorder with a significant unmet medical need. Our product, Endari® (L-glutamine oral powder), received FDA approval in 2017. Endari® is available to reduce the acute complications of sickle cell disease in children 5 years and older. For more information, please read the Full Prescribing Information for Endari® at http://www.EndariRx.com/pi.